ライフサイエンスコーパス: PVR

1 PVR after repair of tetralogy of Fallot has a low and im

2 PVR and mean pulmonary arterial pressure were not signif

3 PVR before RVESVi reaches 82 mL/m(2) confers optimal cha

4 PVR is more frequent with TAVR than surgical aortic valv

5 PVR is potentially a reliable indicator of bone graft in

6 PVR might be treated by rational repositioning of existi

7 PVR uncommonly develops after successful treatment of re

8 PVR was compared with the van Hemert scale scores and an

9 emorrhage (odds ratio [OR], 5.73; P = 0.03), PVR found at initial PPV (OR, 11.94; P = 0.021), and ret

10 The difference between grade B and C-1 PVR was significant (P = 2 x 10(-6)).

11 detachment, significant hypotony, grade C-1 PVR, 4 detached quadrants, and large or giant retinal br

12 Multivariate analysis showed grade C-1 PVR, 4 detached quadrants, and presence of choroidal det

13 With grade B or C-1 PVR, cases with large or giant tears had significantly h

14 silicone oil in patients with grade B or C-1 PVR.

15 ed a reduction in PVR severity of at least 1 PVR class at 1 year.

16 the early control of CMV through the DNAM-1-PVR pathway.

17 In total, 221 PVRs were performed in 220 patients (130 male patients;

18 liferative vitreoretinopathy (PVR) (n = 30), PVR (n = 16) and proliferative diabetic retinopathy (PDR

19 ed the highest correlations (mPAP, r = 0.71; PVR, r = 0.64).

20 Compared with segments without PVR (n=758), PVR segments (n=44) were characterized by lower Delta-Im

21 t was insufficient retinopexy, followed by a PVR-reaction in 37.3%, and new site break in 9.1%.

22 In the analysis of a PVR subgroup, uveitis was not associated with a higher r

23 ts of control patients and those with PVR-A, PVR-B, and PVR-C (n = 10 for each group).

24 2.8 [1.4-5.5, p = 0.003]), whereas abnormal PVR was not predictive of either (HFpEF: 0.9 [0.4-2.0, p

25 We studied whether acute PVR (adenosine and waiting time) and late PVR (at repeat

26 al retinotomy for the management of advanced PVR (grade D) were included in the analysis.

27 T cells and mTOR signaling, whereas advanced PVR is characterized by a chronic monocyte response.

28 rformed before PVR (pPVR), immediately after PVR (median, 6 d), and midterm after PVR (mPVR; median,

29 astolic volume pPVR versus immediately after PVR versus mPVR, 156.1+/-41.9 versus 104.9+/-28.4 versus

30 L/m(2); RVESVi pPVR versus immediately after PVR versus mPVR, 74.9+/-26.2 versus 57.4+/-22.7 versus 5

31 rse remodeling takes place immediately after PVR, followed by a continuing process of further biologi

32 ng intrinsic RV functional improvement after PVR.

33 y after PVR (median, 6 d), and midterm after PVR (mPVR; median, 3 y).

34 n mean renal cortical tissue perfusion after PVR when compared with Voluven (P = 0.033).

35 Survival after PVR in the later era (2005-2010; n=156) was significantl

36 of this meta-analysis demonstrate that after PVR: 1) the RV experiences improvement of its volumes an

37 Events in the first year after PVR are rare, and in select high-risk patients, surgical

38 In the first year after PVR, 2 events occurred.

39 ation, a single event occurred 7 years after PVR.

40 In multivariable analyses, PVR+TVI was associated with an additional 2.3-fold reduc

41 rating characteristic curve [AUC], 0.78) and PVR (AUC, 0.79) and the best mPAP correlation (r = 0.62)

42 The final anatomic success rate was 88%, and PVR was a significant predictor of redetachment (P = 0.0

43 ral target proteins, including the NTB-A and PVR receptors and the host restriction factor tetherin,

44 ol patients and those with PVR-A, PVR-B, and PVR-C (n = 10 for each group).

45 car in the evaluation of TAVR candidates and PVR assessment in the postimplant patient are promising,

46 d, second classification based upon lens and PVR status and third classification based upon AL of the

47 er disease and POPH (as assessed by MELD and PVR, respectively) were significantly associated with wa

48 Overall, these data reveal that MICA and PVR are directly regulated by HCMV IE proteins, and this

49 Drug-induced MICA and PVR gene expression are transcriptionally regulated and

50 nd IE2 stimulated the expression of MICA and PVR, but not ULBP3.

51 t quantification appears to improve mPAP and PVR prediction in noninvasive PH evaluation.Supplemental

52 re, pulmonary vascular resistance [PVR], and PVR and PA pressure-flow response [DeltaPQ] during exerc

53 s (complete/posterior reattachment rates and PVR recurrence) were comparable between the 2 groups.

54 in patients with diabetic tractional RD and PVR than in other patients.

55 Foveal RPE atrophy, CNV recurrence, and PVR carried a worse prognosis.

56 onfer a high risk of childhood-onset RRD and PVR.

57 in different concentrations both in RRD and PVR.

58 ge HCMV strains upregulated MICA, ULBP3, and PVR, with NKG2D and DNAM-1 playing a role in NK cell-med

59 eking treatment and to show worse vision and PVR.

60 106 mmol/L, respectively, after Voluven and PVR infusion (P = 0.032).

61 CAM, activation of endothelial PVR with anti-PVR antibodies or interaction with its ligand, DNAM-1, r

62 and cytokines that accumulate in vitreous as PVR develops, neutralizing vascular endothelial growth f

63 At PVR-TIPS completion, persistence of MPV thrombus was not

64 In grade B PVR, the level 1 failure rate was higher when treated wi

65 vascular magnetic resonance performed before PVR (pPVR), immediately after PVR (median, 6 d), and mid

66 showed a strong negative association between PVR values and van Hemert scale scores, as the healing p

67 mm Hg, and 51 participants had PH defined by PVR of greater than 3 Wood units.

68 rent inferior retinal detachment and grade C PVR after primary encircle scleral buckling (SB group -

69 ent inferior retinal detachment with grade C PVR in phakic eyes.

70 Grade C PVR was a positive predictor for surgical failure.

71 on of RUNX1 reduced proliferation of human C-PVR cells in vitro, and curbed growth of freshly isolate

72 cultures derived from human PVR membranes (C-PVR).

73 l rabbit model of mild PVR developed using C-PVR cells.

74 highlight the importance of the TIGIT/CD226/PVR axis as an immune checkpoint barrier that could hind

75 However, the extent to which the TIGIT/CD226/PVR-axis is affected by HIV-infection has not been chara

76 ioactivity of both experimental and clinical PVR vitreous.

77 its in 12 eyes after surgery for complicated PVR detachments using retinectomies with oil, with an av

78 reater age, more frequent foveal detachment, PVR, and greater RD extent.

79 tients with a history of uveitis who develop PVR do not necessarily have a worse visual outcome or a

80 Early PVR is characterized by activation of T cells and mTOR s

81 Early PVR vitreous showed upregulation of T-cell markers, prof

82 with elevated PVR, and the cause of elevated PVR may be other factors such as pain or anxiety causing

83 on in the majority of patients with elevated PVR, and the cause of elevated PVR may be other factors

84 h leukocyte PECAM, activation of endothelial PVR with anti-PVR antibodies or interaction with its lig

85 In case of established PVR >/= C1, the reattachment rate was not statistically

86 oil for retinal detachment with established PVR (Grade C) were randomized to standard (control) or s

87 CMR-estimated PVR showed adequate agreement with invasive PVR (mean bi

88 h was associated with reductions in exercise PVR and pulmonary Ea.

89 e particularly well correlated with exercise PVR and DeltaPQ.

90 algorithm that did not include pre-existing PVR as an input feature had an AUC of 0.81, a sensitivit

91 better for models that included pre-existing PVR as an input.

92 or alpha, which is required for experimental PVR and is associated with this disease in humans.

93 SV inhibited the progression of experimental PVR in rabbit eyes.

94 ing vitrectomy surgery with silicone oil for PVR.

95 Both IE proteins were instead required for PVR upregulation via a mechanism independent of IE DNA b

96 etinectomies with silicone oil tamponade for PVR-related retinal detachments.

97 Once formed, PVR is difficult to treat.

98 ential expression of specific cytokines from PVR-A to C.

99 n-approved agents could protect the eye from PVR in multiple animal models and to further investigate

100 afely and effectively protected rabbits from PVR in multiple models of disease.

101 CD74) and adhesion molecule pathways (e.g., PVR and ICAM1).

102 Higher PVR before LT was associated with worse survival, as was

103 f EMT in primary cultures derived from human PVR membranes (C-PVR).

104 and curbed growth of freshly isolated human PVR membranes in an explant assay.

105 highly expressed in surgically-removed human PVR specimens.

106 orporating WLenh and series 1 DAenh improved PVR correlation (r = 0.56).

107 n MERIT-1, macitentan significantly improved PVR in patients with inoperable CTEPH and was well toler

108 In PVR vitreous, 29 cytokines were upregulated compared to

109 VR in chronic PH (n = 22); and 3) changes in PVR during vasodilator testing in chronic PH (n = 10).

110 embolization (n = 10); 2) serial changes in PVR in chronic PH (n = 22); and 3) changes in PVR during

111 e monitoring of acute and chronic changes in PVR in PH.

112 l analysis were used to correlate changes in PVR with changes in CMR-quantified PA velocity.

113 Differences in PVR result in significant prognostic divergences in both

114 y of CMR to monitor: 1) an acute increase in PVR generated by acute pulmonary embolization (n = 10);

115 inversely correlated with acute increases in PVR induced by pulmonary embolization (r = -0.92), seria

116 GFs, which, at the concentrations present in PVR vitreous, inhibited non-PDGF-mediated activation of

117 oderate PVR at 30 days showed a reduction in PVR severity of at least 1 PVR class at 1 year.

118 ulmonary vascular function (17% reduction in PVR, 12% reduction in PA elastance [pulmonary Ea], and 2

119 This work shows a critical role for RUNX1 in PVR and supports the feasibility of targeting RUNX1 with

120 choroidal detachment or hypotony, increasing PVR was associated with increasing level 1 failure rates

121 n vitro, and HC-HA/PTX3's ability to inhibit PVR formation warrants evaluation in an animal model.

122 ; 95% CI, 1.05-1.17; P < 0.001), and initial PVR (HR, 1.12 per 100 dynes.s.cm; 95% CI, 1.02-1.23; P =

123 PVR showed adequate agreement with invasive PVR (mean bias -1.1 Wood units,; 95% confidence interval

124 rly tricuspid valve competence than isolated PVR.

125 and mild to severe TR who underwent isolated PVR (66.8%) or PVR+TVI (33.2%).

126 In CF-guided pulmonary vein isolation, PVR is explained by lack of both lesion depth and contig

127 y by binding to the receptor tyrosine kinase PVR, which is necessary and sufficient for intestinal ER

128 PD patients had larger PVR areas immediately after deployment (40.3+/-17.1 vers

129 te PVR (adenosine and waiting time) and late PVR (at repeat) are explained by incomplete transmuralit

130 ion (IL-2, IL-6, and IL-13), whereas in late PVR vitreous, cytokines driving monocyte responses and s

131 -stimulatory receptor CD226 and their ligand PVR are altered in viral infections and cancer.

132 At week 16, geometric mean PVR decreased to 73.0% of baseline in the macitentan gro

133 At 12 months, mean PVR reduction was 258 +/- 135 dyn s cm(-5) in the PADN g

134 ree independent observers (A, B, C) measured PVRs at two different time points during the first and t

135 n of disease in a novel rabbit model of mild PVR developed using C-PVR cells.

136 ucing PVR in patients with greater than mild PVR after balloon-expandable TAVR.

137 mized an ARPE-19 cell culture model to mimic PVR by defining cell density, growth factors, and cultiv

138 ould be positioned successfully with minimal PVR.

139 roke was 1.7%; 1 (1.0%) patient had moderate PVR, whereas none had severe PVR.

140 Most patients with at least moderate PVR at 30 days showed a decrease of PVR severity grade a

141 , 73% of the patients with at least moderate PVR at 30 days showed a reduction in PVR severity of at

142 to moderate, and 3.5% had at least moderate PVR at 30 days.

143 Only patients with at least moderate PVR had higher 1-year mortality (hazard ratio [HR], 2.40

144 R with the SAPIEN 3 valve, at least moderate PVR was rare but associated with increased risk of death

145 stically different (92.6%) from eyes with no PVR (91.1%) irrespective of lens status.

146 t codon 72 between the PVR cases and the non-PVR controls in Spain and Portugal (phase I), but not in

147 Prespecified analysis of PVR in the Placement of Aortic Transcatheter Valves (PAR

148 eived a SAPIEN 3 valve and had assessment of PVR.

149 etinal detachment fails primarily because of PVR.

150 ical and histopathologic characterization of PVR in treated retinoblastoma.

151 moderate PVR at 30 days showed a decrease of PVR severity grade at 1 year.

152 higher risk for development of any degree of PVR (hazard ratio [HR], 2.2; 95% confidence interval [CI

153 ated with an increased risk of any degree of PVR and an increased risk of PVR necessitating an additi

154 est subjects (n = 7) with varying degrees of PVR.

155 rapeutic agent to prevent the development of PVR by targeting EMT of RPE.

156 found to be intrinsic to the development of PVR in rabbit models.

157 udies that reported data about the effect of PVR in patients with repaired tetralogy of Fallot that d

158 We assessed the effect of PVR on 1-year mortality and heart failure rehospitalizat

159 perative RV geometry modulates the effect of PVR; and 6) there is important heterogeneity of the effe

160 Furthermore, expression of PVR was increased on CD4(+) T cells, especially T follic

161 compartment-specific molecular hallmarks of PVR, considering the risk of life-threatening pulmonary

162 We evaluated the impact of PVR-TIPS on liver function, transplant eligibility, and

163 SU9518 was an effective inhibitor of PVR in both fibroblast and Muller cell models of PVR.

164 down of Pvrl1 reduced cell-surface levels of PVR but not levels of Pvr messenger RNA.

165 V on PVR development using a rabbit model of PVR.

166 in both fibroblast and Muller cell models of PVR.

167 evolution, and effect on 1-year outcomes of PVR following TAVR with a third-generation balloon-expan

168 The outcomes of PVR in adults after repair of tetralogy of Fallot at a s

169 ls is a critical step in the pathogenesis of PVR, which is characterized by fibrotic membrane formati

170 g PVR at week 16, expressed as percentage of PVR measured at baseline.

171 velopment of ML models for the prediction of PVR by ophthalmologists without coding experience is fea

172 In the presence of PVR and PDR, the majority of cytokines are upregulated;

173 atinib may be effective in the prevention of PVR.

174 l CTEPH resulted in substantial reduction of PVR at 12 months of follow-up, accompanied by improved 6

175 higher level 2 failure rates, regardless of PVR status (P<0.05).

176 howed RD, 19 (54%) redetached as a result of PVR.

177 morphism is associated with a higher risk of PVR developing after a primary RD.

178 I], 1.1-4.4, P = 0.030) and a higher risk of PVR necessitating an additional procedure (HR, 2.7; 95%

179 tis was not associated with a higher risk of PVR necessitating an additional procedure and did not sh

180 f any degree of PVR and an increased risk of PVR necessitating an additional procedure.

181 d to determine if this decreases the risk of PVR or improves visual outcomes.

182 specific therapeutic target and the stage of PVR.

183 tially life-threatening issue at the time of PVR.

184 er examined the preventive effect of RESV on PVR development using a rabbit model of PVR.

185 ere TR who underwent isolated PVR (66.8%) or PVR+TVI (33.2%).

186 ived 1-L intravenous infusions of Voluven or PVR over 30 minutes in a randomized, double-blind manner

187 and macular volume; (3) development of overt PVR recurrence; (4) complete and posterior retinal reatt

188 PASP, PVR, and PAC were each predictive of incident HF or deat

189 is study, we observed abnormalities of PASP, PVR, and PAC in 12%-18% of elders in the community.

190 Mean values of PASP, PVR, and PAC were 28 +/- 5 mm Hg, 1.7 +/- 0.4 Wood unit,

191 t was associated with abnormalities of PASP, PVR, and PAC.

192 ssociated with a smaller improvement in post-PVR RV/left ventricular ejection fraction.

193 e aimed to assess immediate and midterm post-PVR changes and predictors of reverse remoeling.

194 gorithms for the prediction of postoperative PVR using clinical data from the electronic health recor

195 the curve (AUC) for predicting postoperative PVR was better for models that included pre-existing PVR

196 nical features associated with postoperative PVR were determined by univariate feature selection.

197 (VEGF) A has recently been found to prevent PVR in at least one animal model.

198 interest in developing approaches to prevent PVR.

199 of re-detachment in patients with a primary PVR (p = 0.0003), and in the group with silicone oil as

200 nd a greater proportion demonstrated primary PVR (11/82 patients [13.4%] in 2020 vs. 5/111 patients [

201 However, patients with primary PVR and primary silicone oil fills were at a significant

202 Thus, VEGF promotes PVR by a noncanonical ability to engage platelet-derived

203 We examined if the pixel value ratio (PVR) obtained in routine follow-up digital radiographs c

204 49 of 2,231 patients); the pooled 5-year re-PVR was 4.9% (15 studies; 88 of 1,798 patients).

205 obliterated, we developed PV recanalization (PVR)-transjugular intrahepatic portosystemic shunt (TIPS

206 The poliovirus receptor (PVR) is a ubiquitously expressed glycoprotein involved i

207 d), Nectin-2/CD112, and poliovirus receptor (PVR)/CD155 (DNAM-1 ligand), are often induced on virus-i

208 Pulmonary vein reconnection (PVR) still determines recurrences of atrial fibrillation

209 PS), a pressure visualization and recording (PVR) system with a spatial resolution of 500 microm is d

210 rch (potato-derived) [Plasma Volume Redibag (PVR); Baxter Healthcare, Thetford, United Kingdom] on re

211 demonstrates the efficacy of PD at reducing PVR in patients with greater than mild PVR after balloon

212 Human cytomegalovirus (HCMV) down-regulates PVR expression, but the significance of this viral funct

213 re and even mild paravalvular regurgitation (PVR) are associated with increased mortality following t

214 seal to minimize paravalvular regurgitation (PVR).

215 ve function and para-valvular regurgitation (PVR) after trans-catheter aortic valve replacement (TAVR

216 ertension and pulmonary vascular remodeling (PVR) are common in many lung diseases leading to right v

217 ns for surgical pulmonary valve replacement (PVR) after repair of tetralogy of Fallot have recently b

218 Pulmonary valve replacement (PVR) after repair of tetralogy of Fallot is commonly req

219 Pulmonary valve replacement (PVR) in patients with repaired tetralogy of Fallot provi

220 Fallot require pulmonary valve replacement (PVR), but the evaluation for and management of ventricul

221 S) referred for pulmonary valve replacement (PVR).

222 An important proportion of patients require PVR late after tetralogy of Fallot repair.

223 >=25 mm Hg or pulmonary vascular resistance (PVR) > 400 dyn s cm(-5) based on right heart catheteriza

224 Patients with pulmonary vascular resistance (PVR) >4 WU or right ventricular dysfunction were exclude

225 Additionally, pulmonary vascular resistance (PVR) 2.2 to 3.0 WU, considered previously to be normal,

226 An elevated pulmonary vascular resistance (PVR) before LT was associated with worse survival rate (

227 rm changes in pulmonary vascular resistance (PVR) noninvasively.

228 II-IV with a pulmonary vascular resistance (PVR) of at least 400 dyn.s/cm(5) and a walk distance of

229 re (mPAP) and pulmonary vascular resistance (PVR) with additional receiver operating characteristic c

230 ssure (mPAP), pulmonary vascular resistance (PVR), and cardiac index.

231 ssure (PASP), pulmonary vascular resistance (PVR), and pulmonary arterial compliance (PAC) were measu

232 >25 mm Hg and pulmonary vascular resistance [PVR] >/=240 dynes.s.cm) who were approved for a POPH MEL

233 PA pressure, pulmonary vascular resistance [PVR], and PVR and PA pressure-flow response [DeltaPQ] du

234 The primary endpoint was resting PVR at week 16, expressed as percentage of PVR measured

235 The m20.1 protein of MCMV retains PVR in the endoplasmic reticulum and promotes its degrad

236 y pulmonary embolization (r = -0.92), serial PVR fluctuations in chronic PH (r = -0.89), and acute re

237 Three patients developed severe PVR after sequential thermal laser combined with systemi

238 treated retinoblastoma who developed severe PVR and required enucleation.

239 nt had moderate PVR, whereas none had severe PVR.

240 Finally, although VEGF could promote some PVR-associated cellular responses via VEGF receptors exp

241 Hepa1-6 cells, PVRL1 stabilized cell surface PVR, which interacted with TIGIT on CD8(+) T cells; knoc

242 ulated by HCC cells, stabilizes cell surface PVR, which interacts with TIGIT, an inhibitory molecule

243 e CMV (MCMV) also down-regulates the surface PVR.

244 nt (50% intramuscular paralytic dose in Tg21-PVR mice: log10(7.0)).

245 pressing the human poliovirus receptor (Tg21-PVR) mice, and their antigenicity was characterized by i

246 Further studies demonstrate that PVR resides in the recently identified lateral border re

247 The PVR from radiographs of thirty children with ceramic bon

248 The PVR-TIPS may be considered for patients with obliterativ

249 genotype frequencies at codon 72 between the PVR cases and the non-PVR controls in Spain and Portugal

250 A MCMV mutant lacking the PVR inhibitor was attenuated in normal mice but not in m

251 The reliability of the PVR measurements was assessed using an aluminum step wed

252 thesized that HC-HA/PTX3 could inhibit these PVR-related processes in vitro.

253 In this PVR system, the applied pressure can be recorded without

254 for primary RRD, recurrent detachment due to PVR occurred in 2 eyes (11.1%).

255 ling procedure (SBP) for recurrent RD due to PVR.

256 outside of the PDGF family)] are relevant to PVR pathogenesis because they act on PDGF receptor alpha

257 Of these patients, 55.7% had none-trace PVR, 32.6% had mild, 8.2% had mild to moderate, and 3.5%

258 Freedom from redo surgical or transcatheter PVR was 98% at 5 years and 96% at 10 years for the whole

259 stdilatation (PD) has been proposed to treat PVR without being formally studied.

260 with repaired tetralogy of Fallot undergoing PVR at our institution between 1988 and 2010.

261 with repaired tetralogy of Fallot undergoing PVR with history of ventricular tachycardia or left vent

262 mean age, 35.8+/-10.1 y; 38 male) undergoing PVR were prospectively recruited for cardiovascular magn

263 reduce ERM formation in patients undergoing PVR-related RD surgery.

264 surgery/radiology, these patients underwent PVR-TIPS to potentiate transplant eligibility.

265 elate with elevated postvoid residual urine (PVR).

266 .5-61.2 meters with pulmonary vasodilators), PVR [-3.1 Wood Units (WU), 95% CI: -4.9 to -1.4 WU versu

267 RD) without proliferative vitreoretinopathy (PVR) (n = 30), PVR (n = 16) and proliferative diabetic r

268 reoperative proliferative vitreoretinopathy (PVR) and axial length (AL) of the eye upon the anatomica

269 to predict proliferative vitreoretinopathy (PVR) by ophthalmologists without coding experience using

270 Proliferative vitreoretinopathy (PVR) exemplifies a disease that is difficult to predict,

271 Proliferative vitreoretinopathy (PVR) is a nonneovascular blinding disease and the leadin

272 Proliferative vitreoretinopathy (PVR) is a serious complication of retinal detachment and

273 Proliferative vitreoretinopathy (PVR) is mediated by proliferation and epithelial mesench

274 Proliferative vitreoretinopathy (PVR) is the leading cause of retinal detachment surgery

275 pression of proliferative vitreoretinopathy (PVR) patients.

276 ee cases of proliferative vitreoretinopathy (PVR) that developed after successful treatment of retino

277 rade 0 or B proliferative vitreoretinopathy (PVR) was present and higher level 2 failure rates, regar

278 and grade C proliferative vitreoretinopathy (PVR) was present in 12%.

279 ith primary proliferative vitreoretinopathy (PVR), and/or the necessity of a primary silicone oil fil

280 nt, grade C proliferative vitreoretinopathy (PVR), inferior retinal breaks, inferior retinal involvem

281 out (n = 9) proliferative vitreoretinopathy (PVR), vitreous hemorrhage (n = 10), vitreous opacities (

282 , recurrent proliferative vitreoretinopathy (PVR)-related retinal detachment (n = 18), primary rhegma

283 established proliferative vitreoretinopathy (PVR).

284 degrees of proliferative vitreoretinopathy (PVR).

285 associated proliferative vitreoretinopathy (PVR).

286 related to proliferative vitreoretinopathy (PVR).

287 high-grade proliferative vitreoretinopathy (PVR).

288 tion called proliferative vitreoretinopathy (PVR).

289 to prevent proliferative vitreoretinopathy (PVR).

290 of primary proliferative vitreoretinopathy (PVR).

291 (PDR), and proliferative vitreoretinopathy (PVR).

292 , 2.6), and proliferative vitreoretinopathy (PVR; OR, 17.6) were statistically significant predictors

293 The primary endpoint was PVR at 12 months after randomization.

294 PAenh series 2 correlated best with PVR (r = 0.49).

295 retinal fibrovascular tissue consistent with PVR, and reactive changes in the retinal pigment epithel

296 the gene expression of explanted lungs with PVR, compared with controls.

297 min was significantly lower in segments with PVR (74% versus 104%; P<0.001) and was associated with t

298 e cohorts of control patients and those with PVR-A, PVR-B, and PVR-C (n = 10 for each group).

299 atients surviving to 35 years of age without PVR and with a normal exercise capacity may have had a d

300 Compared with segments without PVR (n=758), PVR segments (n=44) were characterized by l